BIOMAT Database Logo BIOMAT Database Logo

Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. 1996

N Nagai, and M Kinoshita, and H Ogata, and D Tsujino, and Y Wada, and K Someya, and T Ohno, and K Masuhara, and Y Tanaka, and K Kato, and H Nagai, and A Yokoyama, and Y Kurita
Department of Biopharmaceutics, Meiji College of Pharmacy, Tanashi-shi, Tokyo, Japan.

OBJECTIVE The relationships between pharmacokinetic parameters of unchanged cisplatin (CDDP) and several markers for nephrotoxicity after CDDP infusion (80 mg/m2) over 2 and 4 h were quantitated in patients with various cancers (lung, stomach and colon cancers and mediastinal tumor). METHODS Plasma and urinary levels of unchanged CDDP were measured using a specific high-performance liquid chromatography method. Pharmacokinetic parameters were calculated according to the model-independent method. The nephrotoxicity markers, blood urea nitrogen (BUN), serum creatinine (SCr), plasma and urinary beta2-microglobulin (BMGp and BMGu), urinary N-acetyl-beta-D-glucosaminidase (NAG) and creatinine clearance (CCR) were monitored for 30 days following CDDP administration. RESULTS The maximum plasma concentration (Cmax), maximum urinary excretion rate (dAe/dt(max)), area under the plasma concentration-time curve from time zero to infinity (AUC), cumulative amount excreted in urine from time zero to infinity (Ae), total clearance (Clt), renal clearance (Clr) and plasma half-life (t1/2) of unchanged CDDP were not significantly different between the 2-h and 4-h infusion schedules. The values of the nephrotoxicity markers changed significantly following CDDP administration, suggesting that CDDP chemotherapy (80 mg/m2) caused nephrotoxicity. The Cmax of unchanged CDDP was the most informative pharmacokinetic parameter for nephrotoxicity. Cmax was related to maximum BUN, maximum SCr and minimum CCR levels in 27 CDDP treatments according to an exponential model. CONCLUSIONS In order to attain more effective CDDP chemotherapy with minimum nephrotoxicity, the present pharmacokinetic and pharmacodynamic studies suggest that the Cmax or steady-state plasma level of unchanged CDDP should be maintained between 1.5 and 2 microg/ml in a standard continuous infusion schedule over 2 h and 4 h.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D001806 Blood Urea Nitrogen The urea concentration of the blood stated in terms of nitrogen content. Serum (plasma) urea nitrogen is approximately 12% higher than blood urea nitrogen concentration because of the greater protein content of red blood cells. Increases in blood or serum urea nitrogen are referred to as azotemia and may have prerenal, renal, or postrenal causes. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984) BUN,Nitrogen, Blood Urea,Urea Nitrogen, Blood
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes

Related Publications

N Nagai, and M Kinoshita, and H Ogata, and D Tsujino, and Y Wada, and K Someya, and T Ohno, and K Masuhara, and Y Tanaka, and K Kato, and H Nagai, and A Yokoyama, and Y Kurita
[Relationship between plasma and urinary platinum pharmacokinetics with cisplatin nephrotoxicity in breast cancer patients].
March 1992, Zhonghua zhong liu za zhi [Chinese journal of oncology],
N Nagai, and M Kinoshita, and H Ogata, and D Tsujino, and Y Wada, and K Someya, and T Ohno, and K Masuhara, and Y Tanaka, and K Kato, and H Nagai, and A Yokoyama, and Y Kurita
Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
August 2001, European journal of clinical pharmacology,
N Nagai, and M Kinoshita, and H Ogata, and D Tsujino, and Y Wada, and K Someya, and T Ohno, and K Masuhara, and Y Tanaka, and K Kato, and H Nagai, and A Yokoyama, and Y Kurita
Pharmacokinetics and toxicodynamics of cisplatin and its metabolites in rats: relationship between renal handling and nephrotoxicity of cisplatin.
November 2000, The Journal of pharmacy and pharmacology,
N Nagai, and M Kinoshita, and H Ogata, and D Tsujino, and Y Wada, and K Someya, and T Ohno, and K Masuhara, and Y Tanaka, and K Kato, and H Nagai, and A Yokoyama, and Y Kurita
The pharmacokinetics of doxifluridine and 5-fluorouracil after single intravenous infusions of doxifluridine to patients with colorectal cancer.
January 1988, European journal of clinical pharmacology,
N Nagai, and M Kinoshita, and H Ogata, and D Tsujino, and Y Wada, and K Someya, and T Ohno, and K Masuhara, and Y Tanaka, and K Kato, and H Nagai, and A Yokoyama, and Y Kurita
Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
January 1997, Cancer chemotherapy and pharmacology,
N Nagai, and M Kinoshita, and H Ogata, and D Tsujino, and Y Wada, and K Someya, and T Ohno, and K Masuhara, and Y Tanaka, and K Kato, and H Nagai, and A Yokoyama, and Y Kurita
Cisplatin nephrotoxicity in children after continuous 72-h and 3x1-h infusions.
July 2001, Pediatric nephrology (Berlin, Germany),
N Nagai, and M Kinoshita, and H Ogata, and D Tsujino, and Y Wada, and K Someya, and T Ohno, and K Masuhara, and Y Tanaka, and K Kato, and H Nagai, and A Yokoyama, and Y Kurita
Pharmacokinetics of cisplatin regional hepatic infusions.
April 1982, American journal of clinical oncology,
N Nagai, and M Kinoshita, and H Ogata, and D Tsujino, and Y Wada, and K Someya, and T Ohno, and K Masuhara, and Y Tanaka, and K Kato, and H Nagai, and A Yokoyama, and Y Kurita
Cross-over study of penicillin pharmacokinetics after intravenous infusions.
January 1974, Chemotherapy,
N Nagai, and M Kinoshita, and H Ogata, and D Tsujino, and Y Wada, and K Someya, and T Ohno, and K Masuhara, and Y Tanaka, and K Kato, and H Nagai, and A Yokoyama, and Y Kurita
Alfentanil infusions: relationship between pharmacokinetics and pharmacodynamics in man.
May 1987, European journal of anaesthesiology,
N Nagai, and M Kinoshita, and H Ogata, and D Tsujino, and Y Wada, and K Someya, and T Ohno, and K Masuhara, and Y Tanaka, and K Kato, and H Nagai, and A Yokoyama, and Y Kurita
Potential nephrotoxicity of intravenous infusions of naftidrofuryl oxalate.
January 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Copied contents to your clipboard!